Tryp Therapeutics announces research alliance with the University of Michigan 

La Jolla, Calif.–based Tryp (CSE: TRYP) is tapping the University of Michigan to test its TRP-8803 drug formulation against traditional oral formulations of synthetic psilocybin.

The psilocybin-based drug developer will also work with the university to compare TRP-8803 with conventional formulations of synthetic psilocybin. In particular, the university will perform pharmacokinetic analysis for blood samples from patients who received psilocybin via oral and novel delivery methods.

Additionally, Tryp expects the partnership with the University of Michigan to help advance TRP-8803 to Phase 2b clinical trials. The research alliance will explore the psilocybin-induced increase in neurophysiological complexity and psilocybin’s potential to reduce chronic central pain. The University of Michigan also will explore the impact of alternative delivery strategies of psilocybin on pain indices and insular glutamate and gamma-aminobutyric acid (GABA) levels.

Tryp ha…

Read more
  • 0

As interest in psychedelic medicine grows, Big Pharma sits on the sidelines

Image by Ben Johnson from Pixabay

While Big Pharma has yet to embrace psychedelics as potential treatments for depression and other psychiatric disorders, interest in psychedelic medicine is building. 

Earlier this month, Nature Medicine published a Phase 3 study indicating that psychotherapy assisted with methyl​enedioxy​methamphetamine (MDMA) was a more effective treatment for post-traumatic stress disorder (PTSD) than therapy alone. The study authors concluded that MDMA yielded a larger effect size than antidepressants Zoloft (sertraline) and Paxil (paroxetine).

The FDA granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in 2017. Approval could come in 2023, according to The New York Times. 

[Related: Debate series considers the therapeutic promise and pitfalls of psychedelics]

Last month, NEJM summarized the results of a Phase 2 study that found that psil…

Read more
  • 0